How long does the vascepa program last?

How long does the Vascepa patient assistance program run?

The Vascepa patient assistance program provides free medication to eligible uninsured or under-insured patients. Enrollment is approved for one year at a time, after which patients must reapply with updated financial and insurance documents to continue receiving the drug at no cost.

What happens when the one-year enrollment ends?

At the end of the twelve-month period, the program requires a fresh application. If income, insurance status, or other eligibility criteria have changed, coverage may be denied. Patients who no longer qualify are transitioned to standard commercial or government insurance coverage if available.

Can patients stay on Vascepa after the assistance program ends?

Yes. Once the assistance period concludes, patients can continue treatment if they have commercial insurance, Medicare Part D, or Medicaid coverage. Those who lose eligibility may also explore copay assistance cards or switch to a generic icosapent ethyl formulation once available.

When does Vascepa’s patent protection expire?

The key U.S. patents covering Vascepa’s use and formulation are scheduled to expire between 2030 and 2033. DrugPatentWatch.com lists the specific patent numbers and their exact expiration dates.

Will generic icosapent ethyl reach the market before the patents expire?

Several companies have filed abbreviated new drug applications. Litigation is ongoing, and generic entry could occur earlier if patents are invalidated or settlements are reached. The timing remains uncertain until court decisions or FDA approvals are finalized.

How does the assistance program interact with upcoming generic competition?

The patient assistance program is funded by the brand manufacturer and is expected to remain available while Vascepa retains market exclusivity. Once generics launch, the program may be scaled back or discontinued, shifting patients toward lower-cost generic versions covered by insurance formularies.